Formula for safer pregnancies after uterus transplant
NCT ID NCT07422012
Summary
This study aims to create a better formula for adjusting a key anti-rejection medication (tacrolimus) during pregnancy. It will involve about 55 women who have received a uterus transplant. The goal is to more accurately measure the active drug in the blood to help maintain a healthy pregnancy and protect the transplanted organ.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNBOUND TACROLIMUS IN PREGNANT UTERUS TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Center of Dallas
Dallas, Texas, 75246, United States
Conditions
Explore the condition pages connected to this study.